Review



recombinant il 33 ril 33  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    R&D Systems recombinant il 33 ril 33
    Recombinant Il 33 Ril 33, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 123 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant il 33 ril 33/product/R&D Systems
    Average 94 stars, based on 123 article reviews
    recombinant il 33 ril 33 - by Bioz Stars, 2026-02
    94/100 stars

    Images



    Similar Products

    94
    R&D Systems recombinant il 33 ril 33
    Recombinant Il 33 Ril 33, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant il 33 ril 33/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    recombinant il 33 ril 33 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    90
    PeproTech human ril-33
    Human Ril 33, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human ril-33/product/PeproTech
    Average 90 stars, based on 1 article reviews
    human ril-33 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    94
    R&D Systems human ril 33 stimulation
    Human Ril 33 Stimulation, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human ril 33 stimulation/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    human ril 33 stimulation - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    95
    R&D Systems human ril 33
    Human Ril 33, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human ril 33/product/R&D Systems
    Average 95 stars, based on 1 article reviews
    human ril 33 - by Bioz Stars, 2026-02
    95/100 stars
      Buy from Supplier

    90
    R&D Systems human ril-33
    (A) Survival of WT or IL33–/– B6 mice injected i.t. with 1.0 IU/kg bleomycin alone or with 1 μg <t>rIL-33.</t> Data are from 2 pooled experiments. (B) At days 7–8 after bleomycin delivery, bronchoalveolar lavage fluid (BALF) from Il33–/– mice had increased IL-6, G-CSF, LIF, IL-1α, and MCP-1 concentrations, which were significantly reduced by rIL-33 restoration. Data are from 1 experiment representative of 2, and n = 5–6 mice per group. (C and D) Flow cytometric assessment of BALF cells from WT and Il33–/– treated as in A. (C) Frequencies of alveolar macrophages (CD45+CD11bloSiglec-F+) and neutrophils (CD45+CD11bhiSiglec-F–Ly6Ghi). (D) Frequencies of alveolar Ly6Chi inflammatory monocytes (CD45+CD11bhiCD11cloLy6Chi) and Ly6Clo immunosuppressive and reparative monocytes (CD45+CD11bhiCD11cloLy6Clo). Data are representative of 2 independent experiments, with 5–6 mice per group in each experiment. Data are the mean ± SD. P values were determined by log-rank test (A), or 1-way ANOVA followed by Tukey’s multiple comparisons test (B–D). *P < 0.05; **P < 0.01.
    Human Ril 33, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human ril-33/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    human ril-33 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    Image Search Results


    (A) Survival of WT or IL33–/– B6 mice injected i.t. with 1.0 IU/kg bleomycin alone or with 1 μg rIL-33. Data are from 2 pooled experiments. (B) At days 7–8 after bleomycin delivery, bronchoalveolar lavage fluid (BALF) from Il33–/– mice had increased IL-6, G-CSF, LIF, IL-1α, and MCP-1 concentrations, which were significantly reduced by rIL-33 restoration. Data are from 1 experiment representative of 2, and n = 5–6 mice per group. (C and D) Flow cytometric assessment of BALF cells from WT and Il33–/– treated as in A. (C) Frequencies of alveolar macrophages (CD45+CD11bloSiglec-F+) and neutrophils (CD45+CD11bhiSiglec-F–Ly6Ghi). (D) Frequencies of alveolar Ly6Chi inflammatory monocytes (CD45+CD11bhiCD11cloLy6Chi) and Ly6Clo immunosuppressive and reparative monocytes (CD45+CD11bhiCD11cloLy6Clo). Data are representative of 2 independent experiments, with 5–6 mice per group in each experiment. Data are the mean ± SD. P values were determined by log-rank test (A), or 1-way ANOVA followed by Tukey’s multiple comparisons test (B–D). *P < 0.05; **P < 0.01.

    Journal: JCI Insight

    Article Title: IL-33–mediated IL-13 secretion by ST2 + Tregs controls inflammation after lung injury

    doi: 10.1172/jci.insight.123919

    Figure Lengend Snippet: (A) Survival of WT or IL33–/– B6 mice injected i.t. with 1.0 IU/kg bleomycin alone or with 1 μg rIL-33. Data are from 2 pooled experiments. (B) At days 7–8 after bleomycin delivery, bronchoalveolar lavage fluid (BALF) from Il33–/– mice had increased IL-6, G-CSF, LIF, IL-1α, and MCP-1 concentrations, which were significantly reduced by rIL-33 restoration. Data are from 1 experiment representative of 2, and n = 5–6 mice per group. (C and D) Flow cytometric assessment of BALF cells from WT and Il33–/– treated as in A. (C) Frequencies of alveolar macrophages (CD45+CD11bloSiglec-F+) and neutrophils (CD45+CD11bhiSiglec-F–Ly6Ghi). (D) Frequencies of alveolar Ly6Chi inflammatory monocytes (CD45+CD11bhiCD11cloLy6Chi) and Ly6Clo immunosuppressive and reparative monocytes (CD45+CD11bhiCD11cloLy6Clo). Data are representative of 2 independent experiments, with 5–6 mice per group in each experiment. Data are the mean ± SD. P values were determined by log-rank test (A), or 1-way ANOVA followed by Tukey’s multiple comparisons test (B–D). *P < 0.05; **P < 0.01.

    Article Snippet: Human rIL-2 (300 U/ml; Peprotech) alone or with human rIL-33 (50 ng/ml; R&D Systems) was added on day 2.

    Techniques: Injection

    (A and B) Flow cytometric assessment of CD45+CD3+CD4+CD25+ cells isolated from enzymatically digested WT B6 and B6 Il33–/– mouse lung tissue at day 8 after bleomycin revealed that delivery of IL-33 increased ST2+ Tregs in damaged Il33–/– lung tissue. Data depicted in B are the mean ± SD and are representative of 2 independent experiments, with 4–5 mice per group in each experiment. (C) Survival of B6 Foxp3DTR mice injected i.t. with bleomycin alone or with rIL-33 (1 μg i.t.) in the presence of Tregs or following their deletion with diphtheria toxin (15 μg/kg on day –3, –2, and –1, and every other day starting from day 1). Depicted data represent 1 experiment with 6–7 mice per group. P values were determined by 1-way ANOVA followed by Tukey’s multiple comparisons test (B) or log-rank test (C). *P < 0.05; **P < 0.01; ***P < 0.001. NS, not significant.

    Journal: JCI Insight

    Article Title: IL-33–mediated IL-13 secretion by ST2 + Tregs controls inflammation after lung injury

    doi: 10.1172/jci.insight.123919

    Figure Lengend Snippet: (A and B) Flow cytometric assessment of CD45+CD3+CD4+CD25+ cells isolated from enzymatically digested WT B6 and B6 Il33–/– mouse lung tissue at day 8 after bleomycin revealed that delivery of IL-33 increased ST2+ Tregs in damaged Il33–/– lung tissue. Data depicted in B are the mean ± SD and are representative of 2 independent experiments, with 4–5 mice per group in each experiment. (C) Survival of B6 Foxp3DTR mice injected i.t. with bleomycin alone or with rIL-33 (1 μg i.t.) in the presence of Tregs or following their deletion with diphtheria toxin (15 μg/kg on day –3, –2, and –1, and every other day starting from day 1). Depicted data represent 1 experiment with 6–7 mice per group. P values were determined by 1-way ANOVA followed by Tukey’s multiple comparisons test (B) or log-rank test (C). *P < 0.05; **P < 0.01; ***P < 0.001. NS, not significant.

    Article Snippet: Human rIL-2 (300 U/ml; Peprotech) alone or with human rIL-33 (50 ng/ml; R&D Systems) was added on day 2.

    Techniques: Isolation, Injection

    (A) Survival of B6 Il33–/– mice instilled i.t. with bleomycin (1.0 IU/kg) and also treated with i.t. PBS (n = 10) or 1 μg recombinant (r) mouse IL-13 (n = 8). (B) Survival of Treg-depleted mice i.t. instilled with bleomycin (1.0 IU/kg) and 1 μg rIL-33 with or without rIL-13 (1 μg). (C) Weight changes of BALB/c Foxp3Cre mice (n = 7) injected i.t. with bleomycin (6.0 IU/kg) compared with bleomycin-treated Foxp3Cre × Il4/Il13fl/fl (n = 8) or PBS-treated Foxp3Cre mice (n = 3). Data were pooled from 2 separate experiments. (D) Survival of Foxp3Cre (n = 12) and Foxp3Cre × Il4/Il13fl/fl (n = 11) injected i.t. with bleomycin. (E) At day 7 after bleomycin delivery, BALF from Foxp3Cre × Il4/Il13fl/fl had increased IL-6, G-CSF, and MCP-1 concentrations. (F) Flow cytometric analysis of BALF cells at day 7 after bleomycin delivery for alveolar macrophages (CD45+CD11bloSiglec-F+), neutrophils (CD45+CD11bhiSiglec-F–Ly6Ghi), and inflammatory monocytes (CD45+CD11bhiCD24loMHC-IIloLy6Chi). In E and F, data were pooled from 2 independent experiments (n = 5–6 mice per group total). (G) qRT-PCR data of Arg1 expression in cultures of F4/80-purified BALB/c splenic macrophages (Il1rl1+/+ or Il1rl1–/–) incubated for 18 hours under the conditions indicated. Data are from 1 experiment representative of 3 completed. Animal survival was compared by Kaplan-Meier analysis and the log-rank test. Data are the mean ± SD and P values were determined by 2-tailed Student’s t test or 1-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Journal: JCI Insight

    Article Title: IL-33–mediated IL-13 secretion by ST2 + Tregs controls inflammation after lung injury

    doi: 10.1172/jci.insight.123919

    Figure Lengend Snippet: (A) Survival of B6 Il33–/– mice instilled i.t. with bleomycin (1.0 IU/kg) and also treated with i.t. PBS (n = 10) or 1 μg recombinant (r) mouse IL-13 (n = 8). (B) Survival of Treg-depleted mice i.t. instilled with bleomycin (1.0 IU/kg) and 1 μg rIL-33 with or without rIL-13 (1 μg). (C) Weight changes of BALB/c Foxp3Cre mice (n = 7) injected i.t. with bleomycin (6.0 IU/kg) compared with bleomycin-treated Foxp3Cre × Il4/Il13fl/fl (n = 8) or PBS-treated Foxp3Cre mice (n = 3). Data were pooled from 2 separate experiments. (D) Survival of Foxp3Cre (n = 12) and Foxp3Cre × Il4/Il13fl/fl (n = 11) injected i.t. with bleomycin. (E) At day 7 after bleomycin delivery, BALF from Foxp3Cre × Il4/Il13fl/fl had increased IL-6, G-CSF, and MCP-1 concentrations. (F) Flow cytometric analysis of BALF cells at day 7 after bleomycin delivery for alveolar macrophages (CD45+CD11bloSiglec-F+), neutrophils (CD45+CD11bhiSiglec-F–Ly6Ghi), and inflammatory monocytes (CD45+CD11bhiCD24loMHC-IIloLy6Chi). In E and F, data were pooled from 2 independent experiments (n = 5–6 mice per group total). (G) qRT-PCR data of Arg1 expression in cultures of F4/80-purified BALB/c splenic macrophages (Il1rl1+/+ or Il1rl1–/–) incubated for 18 hours under the conditions indicated. Data are from 1 experiment representative of 3 completed. Animal survival was compared by Kaplan-Meier analysis and the log-rank test. Data are the mean ± SD and P values were determined by 2-tailed Student’s t test or 1-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Article Snippet: Human rIL-2 (300 U/ml; Peprotech) alone or with human rIL-33 (50 ng/ml; R&D Systems) was added on day 2.

    Techniques: Recombinant, Injection, Quantitative RT-PCR, Expressing, Purification, Incubation